Journal
BIOINFORMATICS
Volume 37, Issue 4, Pages 578-579Publisher
OXFORD UNIV PRESS
DOI: 10.1093/bioinformatics/btaa727
Keywords
-
Categories
Funding
- Instituto de Salud Carlos III (ISCIII)
- Spanish National Bioinformatics Institute [PT17/0009/0011 -ISCIII-SGEFI/ERDF]
- RETOS [RTI2018-097596-B-I00]
- Paradifference Foundation
- Severo Ochoa FPI
- Comunidad de Madrid [PEJD-2019-PRE/BMD-15732]
- C. de Educacion, Universidades e Formacion Profesional (Xunta de Galicia)
- Competitive Reference Group [ED431C2018/55-GRC]
- Junta de Andalucia [PI-01732017]
Ask authors/readers for more resources
DREIMT is a new hypothesis-generation web tool that performs drug prioritization analysis for immunomodulation, providing a vast amount of information on drugs and immune gene expression signatures. Users can obtain drug-signature association scores, FDRs, and other data from the tool.
Motivation: Drug immunomodulation modifies the response of the immune system and can be therapeutically exploited in pathologies such as cancer and autoimmune diseases. Results: DREIMT is a new hypothesis-generation web tool, which performs drug prioritization analysis for immunomodulation. DREIMT provides significant immunomodulatory drugs targeting up to 70 immune cells subtypes through a curated database that integrates 4960 drug profiles and similar to 2600 immune gene expression signatures. The tool also suggests potential immunomodulatory drugs targeting user-supplied gene expression signatures. Final output includes drug-signature association scores, FDRs and downloadable plots and results tables.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
